Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Robin Meng, MD, PhD, Study Director, Affiliation: AstraZeneca Taiwan
Jia-Horng Wang, MD, Principal Investigator, Affiliation: Taipei Veterans General Hospital,Taiwan
Overall contact:
AstraZeneca Clinical Study Information, Phone: +886-27378623, Email: jade.lien@astrazeneca.com
Summary
A non-interventional study to explore actual asthma control status in real-life environment
and to observe the efficacy after stepped-up to Symbicort SMART or various identical
regimens.
The study will be implemented by screening asthmatic patients from respiratory clinics to
identify those not optimally controlled and required stepping up the controllers to
initiate, or to titrate dose of, ICS/LABA including Symbicort.
Clinical Details
Official title: Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA
Study design: Other, Prospective
Primary outcome: Change in ACQ score from baseline to the mean of all available data from the follow up visits
Secondary outcome: Change in the individual asthma control status & pulmonary function from enrollmentDose/usage of ICS/LABA and relievers & Patient compliance Medical resource utilization
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asthma patient who was partly controlled or uncontrolled by previous controllers of
ICS only, or low dose ICS plus either LABA, leukotriene modifier or theophylline; or
ICS- naïve with severe and persist symptom based on physician's judgment
- According to GINA guideline, who need to step up the controller medications, and
ICS/LABA to be prescribed based on physician's discretion
Exclusion Criteria:
- Patients aged not within limitation refer to label information of various product
prescribed
- Patients who have taken oral corticosteroids within 4 weeks prior to enrollment
- Patients with contraindications to prescribed medication
Locations and Contacts
AstraZeneca Clinical Study Information, Phone: +886-27378623, Email: jade.lien@astrazeneca.com
Research Site, Taipei, Taiwan; Recruiting
Research Site, Taichung, Taiwan; Recruiting
Research Site, Changhua, Taiwan; Recruiting
Research Site, Tainan, Taiwan; Recruiting
Research Site, Kaohsiung, Taiwan; Recruiting
Research Site, Keelung, Taiwan; Not yet recruiting
Additional Information
Starting date: October 2008
Last updated: September 8, 2009
|
